# Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

> **NCT02645149** · PHASE2 · COMPLETED · sponsor: **Melanoma Institute Australia** · enrollment: 216 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Standard therapy or clinical trial
- **DRUG:** Matched targeted therapy
- **DRUG:** Trametinib and / or supportive care
- **DRUG:** CDK4/6 and MEK inhibitor
- **DRUG:** Compassionate Access Targeted Therapy

## Key facts

- **NCT ID:** NCT02645149
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-22
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02645149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02645149, "Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02645149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*